Sunshine Biopharma Inc. filed a Form S-1 registration statement with the SEC on November 18, 2026, covering up to 31,087,198 shares of common stock issuable upon exercise of outstanding Series B Warrants.
Key Highlights
- Shares registered: 31,087,198 shares of common stock, representing the company's estimate of shares potentially issuable upon exercise of Series B Warrants at an assumed adjusted exercise price of $1.00.
- Warrants outstanding: 11,233,359 Series B Warrants are currently outstanding, with a current exercise price of $2.7674 per share and an expiration date of February 15, 2029.
- Original issuance: The Series B Warrants were issued in a public offering that closed on February 15, 2024.
- Recent stock price: The last reported sale price of common stock on Nasdaq on November 17, 2026 was $2.54 per share, according to the filing.
- Reverse splits: Share information in the prospectus reflects four reverse stock splits: 1-for-100 on April 17, 2024; 1-for-20 on August 8, 2024; 1-for-10 on June 1, 2026; and 1-for-20 on October 26, 2026.
- Maximum proceeds: The prospectus states total proceeds before expenses of $31,087,198, assuming all outstanding Series B Warrants are exercised for cash at the current exercise price of $2.7674, with no assurance any warrants will be exercised.
Sunshine Biopharma's S-1 Registration: Series B Warrant Share Issuance Details
Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company incorporated in Colorado and headquartered in Fort Lauderdale, Florida, filed a preliminary Form S-1 registration statement on November 18, 2026. The registration covers 31,087,198 shares of common stock that are or may become issuable upon exercise of the company's outstanding Series B Warrants. According to the filing, the 31,087,198 figure represents the company's estimate based on an assumed adjusted exercise price of $1.00 per share, and both the number of underlying shares and the exercise price remain subject to further adjustment.
The filing discloses that the Series B Warrants carry a current exercise price of $2.7674 per share and expire on February 15, 2029. Holders may exercise the warrants at any time a registration statement covering the underlying shares is effective, by delivering an exercise notice and full payment. If no effective registration statement is in place, holders may instead exercise the warrants on a cashless basis, receiving a net number of shares calculated according to a formula set forth in the warrant. The filing also describes an anti-dilution adjustment provision: if the company sells or agrees to sell shares of common stock at an effective price below the then-current warrant exercise price, the exercise price of the Series B Warrants will be reduced to that lower price and the number of issuable shares will be proportionately adjusted so that the aggregate exercise price remains unchanged.
The company describes itself as a pharmaceutical company operating in oncology and antivirals, with two wholly owned Canadian subsidiaries. Through Nora Pharma Inc., the company reports it currently has 61 generic prescription drugs on the market in Canada. Through Sunshine Biopharma Canada Inc., it develops and sells over-the-counter supplements. The filing also notes a proprietary drug development program comprising K1.1 mRNA, described as an LNP encapsulated mRNA targeted for liver cancer, and SBFM-PL4, described as a protease inhibitor for treatment of SARS Coronavirus infections.
What Was Disclosed
Sunshine Biopharma filed a Form S-1 on November 18, 2026, to register up to 31,087,198 shares of common stock underlying Series B Warrants issued in February 2024, with a current exercise price of $2.7674 per share expiring February 15, 2029.



Please wait processing your request...